Search research articles
Contact Us
Filters
Showing results (61-70 of 118) with videos related to
Page
of 12
Sort By:
British Journal of Haematology
|
July 21, 2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Paolo Strati, Morton Coleman, Rebecca Champion, et al.
Seminars in Oncology
|
April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Morie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
American Journal of Hematology
|
February 28, 2012
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity
Rebecca L Elstrom, Peter Martin, Sandra Hurtado Rua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
Richard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies
Rebecca L Elstrom, Peter Martin, Katya Ostrow, et al.
Hematological Oncology
|
July 27, 2023
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study
Mehdi Hamadani, Morton Coleman, Ralph Boccia, et al.
Leukemia & Lymphoma
|
November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Morton Coleman, David Belada, René-Olivier Casasnovas, et al.
Leukemia & Lymphoma
|
February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
Jodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2004
The radioisotope contributes significantly to the activity of radioimmunotherapy
Thomas A Davis, Mark S Kaminski, John P Leonard, et al.
Leukemia & Lymphoma
|
December 11, 2007
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
Ruben Niesvizky, Déborah Martínez-Baños, Jessica Jalbrzikowski, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 118) with videos related to
Sort By:
Page
of 12
British Journal of Haematology
|
July 21, 2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Paolo Strati, Morton Coleman, Rebecca Champion, et al.
Seminars in Oncology
|
April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Morie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
American Journal of Hematology
|
February 28, 2012
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity
Rebecca L Elstrom, Peter Martin, Sandra Hurtado Rua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
Richard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies
Rebecca L Elstrom, Peter Martin, Katya Ostrow, et al.
Hematological Oncology
|
July 27, 2023
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study
Mehdi Hamadani, Morton Coleman, Ralph Boccia, et al.
Leukemia & Lymphoma
|
November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Morton Coleman, David Belada, René-Olivier Casasnovas, et al.
Leukemia & Lymphoma
|
February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
Jodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2004
The radioisotope contributes significantly to the activity of radioimmunotherapy
Thomas A Davis, Mark S Kaminski, John P Leonard, et al.
Leukemia & Lymphoma
|
December 11, 2007
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
Ruben Niesvizky, Déborah Martínez-Baños, Jessica Jalbrzikowski, et al.
Page
of 12